Cargando…

Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines

Remifentanil is a potent ultra-short acting μ-opioid analgesic drug, frequently used in anaesthesia due to its favorable pharmacodynamic and pharmacokinetic profile. It may be associated with the occurrence of hyperalgesia. Preclinical studies suggest a potential role of microglia, although the mole...

Descripción completa

Detalles Bibliográficos
Autores principales: Dello Russo, Cinzia, Cappoli, Natalia, Tabolacci, Elisabetta, Sollazzi, Liliana, Navarra, Pierluigi, Aceto, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Leibniz Research Centre for Working Environment and Human Factors 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201013/
https://www.ncbi.nlm.nih.gov/pubmed/37220493
http://dx.doi.org/10.17179/excli2022-5667
_version_ 1785045177190055936
author Dello Russo, Cinzia
Cappoli, Natalia
Tabolacci, Elisabetta
Sollazzi, Liliana
Navarra, Pierluigi
Aceto, Paola
author_facet Dello Russo, Cinzia
Cappoli, Natalia
Tabolacci, Elisabetta
Sollazzi, Liliana
Navarra, Pierluigi
Aceto, Paola
author_sort Dello Russo, Cinzia
collection PubMed
description Remifentanil is a potent ultra-short acting μ-opioid analgesic drug, frequently used in anaesthesia due to its favorable pharmacodynamic and pharmacokinetic profile. It may be associated with the occurrence of hyperalgesia. Preclinical studies suggest a potential role of microglia, although the molecular mechanisms have not been fully elucidated. Considering the role of microglia in brain inflammation and the relevant differences among species, the effects of remifentanil were studied on the human microglial C20 cells. The drug was tested at clinically relevant concentrations under basal and inflammatory conditions. In the C20 cells, the expression and secretion of interleukin 6, interleukin 8 and the monocyte chemotactic protein 1 were rapidly induced by a mixture of pro-inflammatory cytokines. This stimulatory effect was sustained up to 24 h. Remifentanil did not exert any toxic effect nor modify the production of these inflammatory mediators, thus suggesting the lack of direct immune modulatory actions on human microglia.
format Online
Article
Text
id pubmed-10201013
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Leibniz Research Centre for Working Environment and Human Factors
record_format MEDLINE/PubMed
spelling pubmed-102010132023-05-22 Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines Dello Russo, Cinzia Cappoli, Natalia Tabolacci, Elisabetta Sollazzi, Liliana Navarra, Pierluigi Aceto, Paola EXCLI J Original Article Remifentanil is a potent ultra-short acting μ-opioid analgesic drug, frequently used in anaesthesia due to its favorable pharmacodynamic and pharmacokinetic profile. It may be associated with the occurrence of hyperalgesia. Preclinical studies suggest a potential role of microglia, although the molecular mechanisms have not been fully elucidated. Considering the role of microglia in brain inflammation and the relevant differences among species, the effects of remifentanil were studied on the human microglial C20 cells. The drug was tested at clinically relevant concentrations under basal and inflammatory conditions. In the C20 cells, the expression and secretion of interleukin 6, interleukin 8 and the monocyte chemotactic protein 1 were rapidly induced by a mixture of pro-inflammatory cytokines. This stimulatory effect was sustained up to 24 h. Remifentanil did not exert any toxic effect nor modify the production of these inflammatory mediators, thus suggesting the lack of direct immune modulatory actions on human microglia. Leibniz Research Centre for Working Environment and Human Factors 2023-02-24 /pmc/articles/PMC10201013/ /pubmed/37220493 http://dx.doi.org/10.17179/excli2022-5667 Text en Copyright © 2023 Dello Russo et al. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ) You are free to copy, distribute and transmit the work, provided the original author and source are credited.
spellingShingle Original Article
Dello Russo, Cinzia
Cappoli, Natalia
Tabolacci, Elisabetta
Sollazzi, Liliana
Navarra, Pierluigi
Aceto, Paola
Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines
title Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines
title_full Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines
title_fullStr Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines
title_full_unstemmed Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines
title_short Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines
title_sort remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201013/
https://www.ncbi.nlm.nih.gov/pubmed/37220493
http://dx.doi.org/10.17179/excli2022-5667
work_keys_str_mv AT dellorussocinzia remifentanildoesnotaffecthumanmicroglialimmuneactivationinresponsetoproinflammatorycytokines
AT cappolinatalia remifentanildoesnotaffecthumanmicroglialimmuneactivationinresponsetoproinflammatorycytokines
AT tabolaccielisabetta remifentanildoesnotaffecthumanmicroglialimmuneactivationinresponsetoproinflammatorycytokines
AT sollazzililiana remifentanildoesnotaffecthumanmicroglialimmuneactivationinresponsetoproinflammatorycytokines
AT navarrapierluigi remifentanildoesnotaffecthumanmicroglialimmuneactivationinresponsetoproinflammatorycytokines
AT acetopaola remifentanildoesnotaffecthumanmicroglialimmuneactivationinresponsetoproinflammatorycytokines